Satralizumab

Satralizumab, sold under the brand name Enspryng, is a humanized monoclonal antibody medication that is used for the treatment of neuromyelitis optica spectrum disorder (NMOSD), a rare autoimmune disease.[3][4] The drug is being developed by Chugai Pharmaceutical, a subsidiary of Roche.[5]

Satralizumab
Monoclonal antibody
TypeWhole antibody
SourceHumanized (from mouse)
Targetinterleukin 6 receptor
Clinical data
Trade namesEnspryng
Other namesSA-237, sapelizumab, satralizumab-mwge
AHFS/Drugs.comMonograph
License data
Routes of
administration		Subcutaneous
ATC code
Legal status
Legal status
Identifiers
CAS Number
DrugBank
UNII
KEGG
Chemical and physical data
FormulaC6340H9776N1684O2022S46
Molar mass143416.47 g·mol−1

The most common side effects include the common cold (nasopharyngitis), headache, upper respiratory tract infection, inflammation of the lining of the stomach, rash, joint pain, extremity pain, fatigue and nausea.[3]

Satralizumab regulates inflammation by inhibiting the interleukin-6 (IL-6) receptor, a key mediator of the immune response.[6]

The U.S. Food and Drug Administration (FDA) considers it to be a first-in-class medication.[7]

Medical uses

Satralizumab is indicated for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adults with a particular antibody – people who are anti-aquaporin-4 or AQP4 antibody-positive.[3][8]

NMOSD is a rare autoimmune disease of the central nervous system that mainly affects the optic nerves and spinal cord.[3] In people with NMOSD, the body's immune system mistakenly attacks healthy cells and proteins in the body, most often those in the optic nerves and spinal cord.[3] Individuals with NMOSD typically have attacks of optic neuritis, which causes eye pain and vision loss.[3] Approximately 50% of people with NMOSD have permanent visual impairment and paralysis caused by NMOSD attacks.[3] Estimates vary, but NMOSD is thought to impact approximately 4,000 to 8,000 Americans.[3]

NMOSD can be associated with antibodies that bind to a protein called aquaporin-4 (AQP4).[3] Binding of the anti-AQP4 antibody appears to activate other components of the immune system, causing inflammation and damage to the central nervous system.[3]

Contraindications

Vaccination with live-attenuated or live vaccines is not recommended during treatment and should be administered at least four weeks before starting satralizumab.[3]

Side effects

The most common side effects observed were the common cold (nasopharyngitis), headache, upper respiratory tract infection, inflammation of the lining of the stomach, rash, joint pain, extremity pain, fatigue and nausea.[3]

The FDA label for satralizumab includes a warning for increased risk of infection, including serious and potentially fatal infections – such as potential reactivation of hepatitis B and tuberculosis.[3][2] Other warnings and precautions for satralizumab include elevated liver enzymes, decreased neutrophil counts and hypersensitivity reactions.[3]

Pharmacology

Mechanism of action

Satralizumab is a humanized IgG2 monoclonal antibody that binds to soluble and membrane-bound human interleukin-6 (IL-6) receptors and thereby prevents IL-6-mediated signal transmission through these receptors.[6]

IL-6 is a pleiotropic cytokine that is produced by a large number of cell types and is involved in a variety of inflammatory processes. Patients with NMO and NMOSD have elevated levels of IL-6 in cerebro-spinal fluid and serum during periods of active disease.[9] Some of the pro-inflammatory processes involved in NMOSD are thought to involve IL-6, including the formation of pathological autoantibodies against aquaporin-4 (AQP4), and the permeability of the blood-brain barrier to mediators of inflammation.[10][4]

Efficacy

The effectiveness and safety of satralizumab for the treatment of neuromyelitis optica spectrum disorder (NMOSD) were demonstrated in two 96-week clinical studies.[3][4][9][11][12]

A study of satralizumab as monotherapy for NMOSD[11] included 95 adult participants, 64 of whom had antibodies against AQP4 (i.e. were anti-AQP4 positive).[3] During this study, treatment with satralizumab reduced the number of NMOSD relapses by 74% in participants who were anti-AQP4 positive compared to treatment with a placebo (inactive treatment).[3]

A study of satralizumab as an adjuvant to immunosuppressant treatment for NMOSD[3][12] included 76 adult participants; 52 were anti-AQP4 positive.[3] Immunosuppressant treatment in combination with satralizumab reduced the rate of relapses in participants who were anti-AQP4 positive by four-fifths compared to immunosuppressant treatment alone.[3][12]

The U.S. Food and Drug Administration (FDA) approved satralizumab based on evidence from two clinical trials (Trial 1/ NCT02073279 and Trial 2/NCT02028884) of 116 participants with NMOSD who were anti-aquaporin-4 (AQP4) antibody positive.[8] The trials were conducted at 62 sites in the United States, Canada, Europe and Asia.[8] Participants received at random either satralizumab or placebo injections according to the schedule.[8] Neither the participants nor the healthcare providers knew which treatment was being given.[8] In the second trial, all participants were also receiving their current immunosuppressive medications for the treatment of NMOSD.[8] The benefit of satralizumab was evaluated by measuring the time to the first attack and comparing it to placebo.[8]

There was no evidence of a benefit in participants who were anti-AQP4 antibody negative in either trial.[3]

Society and culture

Satralizumab was approved for the treatment of AQP4-IgG-seropositive NMOSD in Canada, Japan, and Switzerland.[13][4]

Satralizumab was approved for medical use in the United States in August 2020.[14][8][15] The U.S. Food and Drug Administration (FDA) granted the application for satralizumab fast track and orphan drug designations.[3] The FDA granted the approval of Enspryng to Genentech Inc.[3] Satralizumab is the third approved treatment for NMOSD in the United States.[3]

Names

Satralizumab is the international nonproprietary name (INN)[16] and the United States Adopted Name (USAN).[17]

References
  1. "Satralizumab Product information". Drug Product Database. Health Canada. Retrieved 17 August 2020.
  2. "Enspryng- satralizumab injection, solution". DailyMed. 24 August 2020. Retrieved 24 September 2020.
  3. "FDA Approves Treatment for Rare Disease Affecting Optic Nerves, Spinal Cord". U.S. Food and Drug Administration (FDA). 17 August 2020. Retrieved 17 August 2020. This article incorporates text from this source, which is in the public domain.
  4. Heo, Young-A (14 August 2020). "Satralizumab: First Approval". Drugs. doi:10.1007/s40265-020-01380-2. PMID 32797372.
  5. "Chugai Presents Results from Phase III Study of Satralizumab in NMOSD at ECTRIMS 2018".
  6. Rosso, Mattia; Saxena, Shrishti; Chitnis, Tanuja (26 April 2020). "Targeting IL-6 receptor in the treatment of neuromyelitis optica spectrum: a review of emerging treatment options". Expert Review of Neurotherapeutics. Informa UK Limited. 20 (5): 509–516. doi:10.1080/14737175.2020.1757434. ISSN 1473-7175. PMID 32306778. S2CID 216029479.
  7. "New Drug Therapy Approvals 2020". U.S. Food and Drug Administration (FDA). 31 December 2020. Retrieved 17 January 2021.
  8. "Drug Trials Snapshots: Enspryng". U.S. Food and Drug Administration (FDA). 14 August 2020. Retrieved 13 September 2020. This article incorporates text from this source, which is in the public domain.
  9. "Enspryng". compendium.ch (in German). 2020-07-08. Retrieved 2020-08-10.
  10. Duchow, Ankelien; Paul, Friedemann; Bellmann-Strobl, Judith (13 April 2020). "Current and emerging biologics for the treatment of neuromyelitis optica spectrum disorders". Expert Opinion on Biological Therapy. Informa UK Limited. 20 (9): 1061–1072. doi:10.1080/14712598.2020.1749259. ISSN 1471-2598. PMID 32228250. S2CID 214750971.
  11. Traboulsee A, Greenberg BM, Bennett JL, Szczechowski L, Fox E, Shkrobot S, et al. (May 2020). "Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double-blind, multicentre, placebo-controlled phase 3 trial". The Lancet. Neurology. Elsevier BV. 19 (5): 402–412. doi:10.1016/s1474-4422(20)30078-8. PMID 32333898. S2CID 216055515.
  12. Yamamura T, Kleiter I, Fujihara K, Palace J, Greenberg B, Zakrzewska-Pniewska B, et al. (November 2019). "Trial of Satralizumab in Neuromyelitis Optica Spectrum Disorder". The New England Journal of Medicine. Massachusetts Medical Society. 381 (22): 2114–2124. doi:10.1056/nejmoa1901747. PMID 31774956.
  13. "Enspryng (satralizumab)". Roche. Retrieved 9 August 2020.
  14. "Enspryng: FDA-Approved Drugs". U.S. Food and Drug Administration (FDA). Retrieved 17 August 2020.
  15. "Drug Approval Package: Enspryng". U.S. Food and Drug Administration (FDA). 11 September 2020. Retrieved 13 September 2020.
  16. World Health Organization (2017). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 78". WHO Drug Information. 31 (3): 552. hdl:10665/330961. License: CC BY-NC-SA 3.0 IGO.
  17. "Statement On A Nonproprietary Name Adopted By The USAN Council - Satralizumab]" (PDF). American Medical Association.
  • "Satralizumab". Drug Information Portal. U.S. National Library of Medicine.
  • Clinical trial number NCT02028884 for "Efficacy and Safety Study of Satralizumab (SA237) as Add-on Therapy to Treat Participants With Neuromyelitis Optica (NMO) and NMO Spectrum Disorder (NMOSD)" at ClinicalTrials.gov</ref>
  • Clinical trial number NCT02073279 for "Efficacy and Safety Study of Satralizumab (SA237) as Monotherapy to Treat Participants With Neuromyelitis Optica (NMO) and Neuromyelitis Optica Spectrum Disorder (NMOSD)" at ClinicalTrials.gov
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.